Get the Stockscreener App
0.7659
3.64%
0.0243
Tscan Therapeutics Inc stock is traded at $0.7659, with a volume of 86,283.
It is up +3.64% in the last 24 hours and down -21.58% over the past month.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$0.7416
Open:
$0.756
24h Volume:
86,283
Relative Volume:
0.12
Market Cap:
$50.93M
Revenue:
$9.14M
Net Income/Loss:
$-124.31M
P/E Ratio:
-0.8001
EPS:
-0.9573
Net Cash Flow:
$-125.43M
1W Performance:
-9.19%
1M Performance:
-21.58%
6M Performance:
-24.65%
1Y Performance:
-57.54%
1-Day Range:
$0.74
$0.7794
1-Week Range:
$0.732
$0.892
52-Week Range:
$0.732
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.7794 | 50.21M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
473.17 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
708.65 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
861.97 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.79 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
318.48 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TScan Therapeutics Inc (TCRX) Institutional Confidence - TradingKey
TScan Therapeutics Inc (TCRX) Income Statement - TradingKey
TScan Therapeutics Inc (TCRX) Cash Flow - TradingKey
TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TScan Therapeutics Inc (TCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TCRX|TScan Therapeutics Inc|Price:0.765|Chg%:-0.029 - TradingKey
TScan Therapeutics Inc (TCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TScan Therapeutics Inc (TCRX) Balance Sheet - TradingKey
TScan Therapeutics, Inc. Revenue Breakdown – NASDAQ:TCRX - TradingView
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc (TCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TCRX|TScan Therapeutics Inc|Price:0.782|Chg%:-0.012 - TradingKey
TScan Therapeutics Inc (TCRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
TScan’s TSC-101 Trial: A New Cell Therapy Bet in Transplant Oncology - TipRanks
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
Cellares and Sonoma partner to automate cell therapy manufacturing - Yahoo Finance
TScan Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue PhaseGuidance Update - dars.gov.et
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - AOL.com
A Quick Look at Today's Ratings for TScan Therapeutics(TCRX.US), With a Forecast Between $5 to $7 - Moomoo
TScan Therapeutics (TCRX) Morgan Stanley 23rd Annual Global Healthcare Conference summary - Quartr
TScan Therapeutics (TCRX) Q4 2025 earnings summary - Quartr
Enterprise value to EBITDA forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics (TCRX) Stock Analysis Report | Financials & Insights - Benzinga España
Enterprise value to EBIT forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics at H.C. Wainwright: phase iii push gains pace By Investing.com - Investing.com Canada
TScan Therapeutics at H.C. Wainwright: phase iii push gains pace - Investing.com
Enterprise value to revenue forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
Price to sales forward of TScan Therapeutics, Inc. – BOATS:TCRX - TradingView
Price to earnings forward of TScan Therapeutics, Inc. – BOATS:TCRX - TradingView
TScan Therapeutics (TCRX) Slips 4.6% as Biotech Momentum Fades Near $0.84 Support TestPositive Gamma - dars.gov.et
TScan Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRX) - TradingView
TCRX Forecast — Price Target — Prediction for 2027 - TradingView
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire
TScan Therapeutics to speak at H.C. Wainwright cell therapy event June 30 - Stock Titan
H.C. Wainwright reiterates Tscan stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Tscan stock rating on trial data By Investing.com - Investing.com South Africa
TCRX Reiterated by Wedbush -- Price Target Maintained at $5.00 - GuruFocus
TCRX Reiterated by Needham -- Price Target Maintained at $6.00 - GuruFocus
TScan Therapeutics Price Target Maintained With a $6.00/Share by Needham - Moomoo
H.C. Wainwright Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Sahm
TScan reports Phase 1 data for TSC-101 blood cancer trial - grafa.com
Form 8K Tscan Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial - TipRanks
TScan reports trial data for blood cancer treatment TSC-101 - Investing.com
TScan reports trial data for blood cancer treatment TSC-101 By Investing.com - Investing.com Australia
TCRX: Cohort C results support advancing TSC-101 to Phase 3, showing high efficacy and safety - TradingView
TScan Therapeutics (TCRX) shows strong TSC-101 Phase 1 data, plans pivotal trial - Stock Titan
TScan Therapeutics Announces Positive Initial Data from - GlobeNewswire
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
0.27%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):